Efficacy observation of wound care ointment (suile) on incision healing after mixed hemorrhoid surgery
摘要
Postoperative complications, including severe pain, perianal edema, and prolonged wound healing, significantly impact patient recovery following mixed hemorrhoid surgery. This study aimed to evaluate the clinical efficacy of a topical wound care ointment (Suile) in promoting postoperative recovery and tissue remodeling.
MethodsIn this randomized controlled trial, 78 patients with stage III–IV mixed hemorrhoids were enrolled and allocated to either a treatment group (topical Suile ointment containing bismuth subgallate and borneol) or a control group (standard povidone-iodine care). Primary and secondary outcomes included pain intensity (Visual Analog Scale, VAS), wound edema scores, scar formation (Vancouver Scar Scale, VSS), and clinical cure rate. Data were analyzed using repeated-measures ANOVA with Bonferroni post-hoc corrections to assess longitudinal recovery patterns.
ResultsBy day 28, the treatment group demonstrated a significantly higher clinical cure rate compared to the control group (69.23% vs. 35.90%, P < 0.01). Repeated-measures ANOVA revealed highly significant improvements in the treatment group for both pain and scar formation. Specifically, VAS scores were significantly lower in the Suile group from days 3 to 14 (P < 0.001), with a large effect size at the primary endpoint (day 7, Cohen’s d = 0.88). Furthermore, Suile application led to significantly superior scar outcomes (VSS scores) by the end of the follow-up period (Group effect P < 0.001; day 28 P < 0.001). While wound edema scores were lower in the treatment group at several time points, the overall group effect for edema did not reach statistical significance (P = 0.146). No serious adverse events were reported.
ConclusionTopical application of Suile ointment significantly alleviates postoperative pain, enhances the quality of scar formation, and accelerates overall wound healing after mixed hemorrhoid surgery. These findings suggest that Suile is a safe and effective therapeutic option for optimizing postoperative recovery in proctological practice.
Trial registrationChinese Clinical Trial Registry (ChiCTR), ChiCTR2600123181. Registered on 22 April 2026. Retrospectively registered.The trial was registered retrospectively due to administrative delays; however, the study protocol and outcomes were defined prior to patient enrollment.”